Research published in the European Journal of Clinical Pharmacology has shown that the US Food and Drug Administration consistently beats other agencies to the finishing line in approving new drugs.
An analysis of data from the last decade shows that in two thirds of cases, the FDA was faster than either the European Medicines Agency or Switzerland’s Swissmedic in reaching approval.
The study, which looked at regulatory information, the approval date and indication for each drug, found that from 2007 to 2016, a total of 134 new drugs were approved by these three regulatory agencies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze